When performing a risk reducing bilateral BSO for women with a BRCA1 or BRCA2 mutation, a STIC will be found in approximately 3.5-5.5% of patients [48-49]. In women having an opportunistic salpingectomy for benign disease or in women with a high-risk family history, STIC may be found in approximately 0.6-1.1% of patients.

When an isolated STIC is identified during risk-reducing BSO for BRCA1 or BRCA2, a referral should be made to BC Cancer for consideration of completion surgical staging (minimum washings, omentectomy, directed biopsies, +/- hysterectomy). Approximately 10% of high-risk women (with BRCA1 or BRCA2 mutations) with a STIC will have a concurrent HGSC of the ovary following surgical staging [51]. In addition, these patients are at risk of developing primary peritoneal carcinoma, the median time to the development being 4-6 years. The 5-year risk is 10.5%, and the 10-year risk is 27.5% [52]. However, based on currently knowledge, only those with invasive disease found at the time of completion surgery should be offered post-operative chemotherapy.

When an isolated STIC is identified in a patient at 'low risk'/general population, a referral should be made to both BC Cancer Surgical Gynecologic Oncology for consideration of completion surgical staging as well as to the BC Cancer Hereditary Cancer Program. These women have an elevated risk (~30%) of carrying a germline BRCA1 or BRCA2 mutation. These patients also are at risk of developing subsequent primary peritoneal carcinoma [53].